New Amsterdam Sciences
2012
FOUNDED
PRIVATE
STATUS
Angel
LATEST DEAL TYPE
$250K
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of anti-idiopathic pulmonary fibrosis drug. The company develops anti-idiopathic pulmonary fibrosis drug which is used in curing influenza infection, solid tumors and helps in wound healing.
Website
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 14362 North Frank Lloyd Wright Boulevard
- Suite 1000
- Scottsdale, AZ 85260
- United States
+1 (480) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore New Amsterdam Sciences’s full profile, request a free trial.
New Amsterdam Sciences Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 19-Nov-2015 | $250K | 00000 | Completed | Startup | |
| 1. Grant | 11-Mar-2014 | Completed | Startup |
New Amsterdam Sciences Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| National Institutes of Health | Government | Minority | 000 0000 | 000000 0 |
New Amsterdam Sciences Executive Team (1)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Jerry Toepfer | Founder & Vice President |
New Amsterdam Sciences Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Jill Anderson JD | New Amsterdam Sciences | Board Member | 000 0000 | |
| Michael Wilhelm | New Amsterdam Sciences | Board Member, Chief Executive Officer & Director of Strategic Partnering and Public Relations | 000 0000 | |
| Theodore Staahl MD | New Amsterdam Sciences | Board Member | 000 0000 |